Hypertension, proteinuria, and antagonism of vascular endothelial growth factor signaling: clinical toxicity, therapeutic target, or novel biomarker?

J Clin Oncol. 2007 Jul 20;25(21):2993-5. doi: 10.1200/JCO.2007.11.5113.
No abstract available

Publication types

  • Comment
  • Editorial

MeSH terms

  • Angiogenesis Inhibitors / adverse effects*
  • Angiogenesis Inhibitors / therapeutic use
  • Biomarkers / analysis
  • Clinical Trials, Phase I as Topic
  • Drug Approval
  • Drug Delivery Systems
  • Evaluation Studies as Topic
  • Female
  • Humans
  • Hypertension / chemically induced*
  • Male
  • Maximum Tolerated Dose
  • Neoplasms / drug therapy*
  • Neoplasms / mortality
  • Neovascularization, Pathologic / prevention & control
  • Prognosis
  • Proteinuria / chemically induced*
  • Risk Assessment
  • Signal Transduction / drug effects
  • Survival Analysis
  • Treatment Outcome
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors*
  • Vascular Endothelial Growth Factor A / physiology

Substances

  • Angiogenesis Inhibitors
  • Biomarkers
  • Vascular Endothelial Growth Factor A